InvestorsHub Logo
Followers 28
Posts 2529
Boards Moderated 0
Alias Born 05/08/2015

Re: StealthGold post# 208119

Wednesday, 05/04/2022 10:51:46 AM

Wednesday, May 04, 2022 10:51:46 AM

Post# of 232645
Wrong again!

Promising Phase II Results for Hard-to-Treat Liver Disease
CytoDyn shared positive results from its Phase II clinical study on the effectiveness of leronlimab against nonalcoholic steatohepatitis (NASH).

The NASH trial achieved the primary endpoint of proton density fat fraction (PDFF) and the secondary endpoint of cT1. PDFF is an MRI-derived biomarker for fatty deposition, while cT1 is an iron-corrected T1 mapping indicator of fibrosis and liver inflammation. Both endpoints were used to assess the NASH risk.

https://www.biospace.com/article/cytodyn-posts-positive-results-from-phase-ii-nash-trial-for-leronlimab/

We do not know if NASH met its end points as the data has not been published.


My comments are just my opinions and should NOT be taken as investment advice.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News